EBTATE is under clinical development by Molecular Targeting Technologies and currently in Phase I for Neuroendocrine Tumors. According to GlobalData, Phase I drugs for Neuroendocrine Tumors have a 74% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how EBTATE’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

EBTATE overview

177-Lu-DOTA-EB-TATE is under development for the treatment of neuroendocrine tumors, metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs), Hurthle cell thyroid cancer, hematological tumor and nasopharyngeal cancer. 177Lu-DOTA-TATE is administered as an intravenous infusion. The drug candidate is a radioconjugate consisting of somatostatin analog octreotide conjugated to radioisotope 177 lutetium via the chelator 1,4,7,10- tetraazacyclododecane-N,N’,N”, N”’-tetraacetic acid (DOTA). The drug candidate acts by targeting Somatostatin Receptor Type 2.

Molecular Targeting Technologies overview

Molecular Targeting Technologies (MTTI) is a biotechnology company that develops novel technologies for the treatment and diagnosis of human diseases. The company offers therapeutic and diagnostic pipelines including rabies mab, BPRDP056, EBTATE, EBRGD, exoblock, tdura, 18f-fluoro glucaric acid, 99m tc-glucarate, psvue-eye drop and cyph-11. MTTI pipeline indications include rabies, multiple cancers, neuroendocrine tumors, hurthle cell thyroid cancer, nasopharyngeal cancer, glioblastoma multiforme, non-small cell lung cancer, advanced melanoma immunotherapy, miscellaneous cancers, cardiac trauma, ocular diseases and ovarian cancer. MTTI is headquartered in West Chester, Pennsylvania, the US.

For a complete picture of EBTATE’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 20 May 2024

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.